Clinical trials: Prostate
Prostate Cancer (Post Prostatectomy), Urinary Continence
Analysis of Immediate Urinary Continence Predictors After RS-RARP
This study is a retrospective, single-center clinical trial. It aims to retrospectively analyze the immediate postoperative urinary continence recovery in prostate cancer patients who underwent Retzius-sparing robot-assisted…
- Conditions
- Prostate Cancer (Post Prostatectomy), Urinary Continence, Retzius-sparing Robot-assisted Radical Prostatectomy
- Trial name
- NCT06850116
- Testing
- Retzius-sparing robot-assisted radical prostatectomy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer
HRQOL in Prostate Cancer Patients Treated With Radiotherapy
The study primarily aims at evaluating health-related quality of life after radiotherapy for prostate cancer, using modern hypofractionated radiotherapy schedules. Study design is a prospective observational cohort study.
- Trial name
- PRORAD (NCT05645237)
- Testing
- radiotherapy
- Where
- Netherlands
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer
Brachytherapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells.
- Trial name
- NCT00003312
- Testing
- iodine I 125
- Where
- 258 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Radiation Therapy Oncology Group
Prostatic Neoplasms
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
The purpose of this study is to see if sequence inversion of Intensity - modulated Radiotherapy (IMRT) for prostate cancer, can improve the safety and deliverability of concurrent docetaxel chemotherapy with long - term hormonal…
- Trial name
- NCT00452556
- Testing
- Docetaxel, Leuprolide Acetate (Eligard®), Intensity-Modulated Radiotherapy
- Where
- Canada
- Volunteers
- 86 people
- Sponsor
- Nova Scotia Cancer Centre
Prostate Cancer
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).
- Trial name
- CAMON (NCT00919477)
- Where
- 160 sites in Japan
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Prostate Cancer
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy.
- Trial name
- NCT00003256
- Testing
- alvocidib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Metastatic
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects of Radium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone Castrate-Resistant…
- Trial name
- Post-eRADicAte (NCT03414437)
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Carolina Research Professionals, LLC
Prostate Cancer
Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate
The purpose of the study is to assess the safety of four different doses of radiation therapy followed by to surgery to remove prostate tumor.
- Trial name
- NCT00691977
- Testing
- Radiation Therapy followed by prostatectomy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
This is a multicenter, prospective, randomized, controlled, open-label, assessor-blinded, non-inferiority trial evaluating whether pelvic drainage can be safely omitted after robot-assisted radical prostatectomy (RARP).
- Trial name
- POND-RARP (NCT07887321)
- Testing
- No Pelvic Drain Placement, Pelvic Drain Placement
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai East Hospital
Adenocarcinoma of the Prostate
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
- Trial name
- DRibble (NCT02234921)
- Testing
- Cyclophosphamide, DRibble Vaccine, HPV Vaccinations
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UbiVac
Breast Cancer, Bladder Cancer
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid…
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer
- Trial name
- NCT00579514
- Testing
- PCR/PCR/LDR Strategy
- Where
- United States
- Volunteers
- 21,081 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor
Genistein is a natural product found in soy beans; its consumption has been associated with a low incidence of metastatic prostate cancer.
- Trial name
- NCT00001696
- Testing
- Genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Prostate Cancer
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer.
- Trial name
- NCT01048151
- Testing
- TNFerade™ Biologic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GenVec
Prostate Cancer
Comparison of a Novel Transperineal Targeted Fusion Biopsy System to Conventional Transrectal Targeted Fusion Biopsy
This study is designed as a randomized control trial which intends to determine if transperineal (TP) targeted biopsy is not inferior to transrectal (TR) targeted biopsy for diagnosis of clinically significant prostate cancer…
- Trial name
- NCT03936127
- Testing
- Ultrasound (US) Targeted Fusion Biopsy
- Where
- Canada
- Volunteers
- 360 people
- Sponsor
- Dr. Nicola Schieda
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer, Lower Urinary Tract Symptoms (LUTS)
Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session.
- Conditions
- Prostate Cancer, Lower Urinary Tract Symptoms (LUTS), Benign Prostatic Hyperplasia
- Trial name
- Bioblation (NCT07526675)
- Testing
- Bioblation
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Benha University
Prostate Cancer
Intensity Modulated Versus Interstitial - Radiation Therapy
Purpose: The purpose of this trial is to compare two different treatment options for patients with low risk and low-tier intermediate risk prostate cancer.
- Trial name
- NCT00407875
- Testing
- Intensity Modulated External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasms
Taxotere Prostate Cancer New Indication Registration Trial in China
To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.
- Trial name
- NCT00436839
- Testing
- Docetaxel, Mitoxantrone, Prednisone
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Sanofi
Prostate Cancer
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00023829
- Testing
- bicalutamide, flutamide, releasing hormone agonist therapy
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Selenium in Preventing Prostate Cancer
RATIONALE: Selenium supplements may stop or delay the development of prostate cancer in patients at high risk of prostate cancer. It is not yet known which dose of selenium may be more effective in preventing prostate cancer.
- Trial name
- NCT00978718
- Testing
- high-selenium baker's yeast, selenium
- Volunteers
- 700 people
- Sponsor
- University of Arizona